Investors in Itaconix (ITX) received a clearer picture of the company’s finances on 8 September 2026, when the plant-based polymer specialist published its interim results and lifted its Itaconix revenue guidance to at least $14.8 million for the full year, alongside a forecast of small positive adjusted EBITDA (earnings before interest, tax, depreciation, and amortisation, stripping out non-cash and exceptional items) for 2026. The share price barely moved, hovering around 207p, which tells you the market wants to see cash, not just guidance.
Itaconix Revenue Guidance Gets an Upgrade
The $14.8 million target is a step up from management’s own earlier forecasts. At a trading update in early 2026, Yahoo Finance reported that the company had pencilled in full-year revenues of $13.3 million and adjusted EBITDA of $300,000. The H1 2026 results, filed as a regulatory news announcement on the London Stock Exchange, pushed both figures higher.
To understand why that upgrade matters, it helps to see where Itaconix has come from. Full-year 2025 revenues rose 61% to $10.5 million, passing the $10 million mark for the first time, up from $6.5 million in 2024, according to Yahoo Finance Canada. Gross profit reached $3.6 million, and the gross profit margin in the core Itaconix Performance Ingredients segment hit 41%.
That kind of top-line momentum is the foundation for the H1 2026 results headline, which the company itself described as ‘Strong revenue growth and break-even adjusted EBITDA.’
From Loss-Making to Break-Even: What the Numbers Show
The losses are shrinking fast. Adjusted EBITDA losses in 2025 narrowed to $600,000, down from $1.8 million in 2024. Net losses (the bottom-line figure after all costs, including non-cash items) fell to $1.4 million from $2.0 million over the same period, per the Yahoo Finance Canada report.
Those are meaningful directional moves. But the question the flat share price is effectively asking is: when does this translate into actual cash being generated, rather than losses simply getting smaller?
The cash position gives some context. Itaconix ended 2025 with net cash and investments of $4.4 million, down from $6.7 million at the end of 2024, according to Yahoo Finance. That $2.3 million drawdown (cash consumed during the year before the business reaches self-funding) over 2025 is the figure investors should hold in mind. If the 2026 guidance is achieved and adjusted EBITDA turns modestly positive, the rate of cash consumption should slow. Whether it stops entirely, and when, remains the open question.
Itaconix describes itself as a leading innovator in high-performance plant-based specialty polymers used in everyday consumer products, particularly homecare detergents. Its three segments, according to CNBC, are Itaconix Performance Ingredients, SPARX Formulated Solutions, and BIO*Asterix. Revenue growth has been driven across all three. During 2025, the company developed new unit dose detergent formulations for 17 North American brands through its SPARX programme, and launched an e-commerce platform for its BIO*Asterix specialty monomers and resins business.
On the stock itself, MarketBeat data shows ITX opened 2026 at GBX 106.26 and had risen approximately 75% to around GBX 185.98 at the time of that data. The company does not pay a dividend, which means the entire investment case rests on the share price and the eventual path to profitability. For ISA or SIPP holders who have been watching this one, the growth story is holding up; the cash generation story is still being written.
The half-year results were filed with the OTC Markets as part of the company’s reporting obligations, covering the period ended 30 June 2026, and published on 8 September 2026.
The binary moment for ITX holders is the full-year result. If revenues clear the $14.8 million guidance threshold and adjusted EBITDA stays positive, the argument for a declining cash burn becomes harder to dismiss. A miss on either line, with the cash pile already reduced to $4.4 million, would sharpen the funding question considerably.
